Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo

  • Authors:
    • Shizuka Tsukagoshi
    • Yasushi Saga
    • Norihiko Suzuki
    • Akio Fujioka
    • Fumio Nakagawa
    • Masakazu Fukushima
    • Mitsuaki Suzuki
  • View Affiliations

  • Published online on: May 1, 2003     https://doi.org/10.3892/ijo.22.5.961
  • Pages: 961-967
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metastasis or progression of ovarian cancer cells is known to be due to the action of various angiogenic factors. We determined the expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor (TP/PD-ECGF) and vascular endothelial growth factor (VEGF) in cell lines established from 3 serous adenocarcinomas, 3 clear cell carcinomas and 2 mucinous carcinomas of the human ovary. TP activity and the TP mRNA level were much higher in the serous adenocarcinoma cells than in the clear cells and mucinous carcinoma cells, and TP expression was extremely low in the clear cell carcinoma cells. Expression of VEGF mRNA was variable, but not significantly different between the 3 histological types of ovarian cancer. In vivo angiogenesis in the ovarian cancer cells was evaluated by the dorsal air sac assay and revealed that SHIN-3 and HRA serous adenocarcinoma cells, which have high levels of TP expression, induced angiogenesis, while KK clear cell carcinoma cells with low TP expression, did not. The degree of ovarian-cancer-induced angiogenesis seemed to be independent of expression of VEGF in the cells. To confirm that the serous adenocarcinoma-induced angiogenesis is dependent on TP levels, a potent and specific inhibitor of TP was administered orally to mice implanted with a chamber containing SHIN-3 or HRA cells. The TP inhibitor significantly inhibited the angiogenesis induced by the serous adenocarcinoma cells. These results suggest that the angiogenic potency of ovarian cancer cells differs with the histological type and is controlled by expression of TP/PD-ECGF, not by VEGF, and that TP-mediated angiogenesis may be the main factor responsible for progression or metastasis of ovarian serous adenocarcinomas.

Related Articles

Journal Cover

May 2003
Volume 22 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tsukagoshi S, Saga Y, Suzuki N, Fujioka A, Nakagawa F, Fukushima M and Suzuki M: Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo. Int J Oncol 22: 961-967, 2003.
APA
Tsukagoshi, S., Saga, Y., Suzuki, N., Fujioka, A., Nakagawa, F., Fukushima, M., & Suzuki, M. (2003). Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo. International Journal of Oncology, 22, 961-967. https://doi.org/10.3892/ijo.22.5.961
MLA
Tsukagoshi, S., Saga, Y., Suzuki, N., Fujioka, A., Nakagawa, F., Fukushima, M., Suzuki, M."Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo". International Journal of Oncology 22.5 (2003): 961-967.
Chicago
Tsukagoshi, S., Saga, Y., Suzuki, N., Fujioka, A., Nakagawa, F., Fukushima, M., Suzuki, M."Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo". International Journal of Oncology 22, no. 5 (2003): 961-967. https://doi.org/10.3892/ijo.22.5.961